 SAN DIEGO, June 04, 2021 GLOBE NEWSWIRE -- TRACON Pharmaceuticals NASDAQ:TCON, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, today presented updated data from the Companys Phase 1 study of TJ004309 and Tecentriq atezolizumab at the American Society of Clinical Oncology ASCO virtual annual meeting. 